Cytori Therapeutics, Inc. (CYTX): John David Harris , VP and GM Cell Therapy of Cytori Therapeutics, Inc. purchased 2,000 shares on May 13, 2016. The Insider buying transaction was reported by the company on May 16, 2016 to the Securities and Exchange Commission. The shares were purchased at $2.71 per share for a total value of $5,420.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 9, 2016, David Rickey (director) purchased 150,000 shares at $0.19 per share price.On Sep 8, 2015, Tommy G Thompson (director) purchased 25,449 shares at $0.38 per share price.Also, On Sep 3, 2015, Jeremy B. Hayden (General Counsel & VP of BD) purchased 8,200 shares at $0.35 per share price.On Aug 31, 2015, Marc H Hedrick (CEO) purchased 11,200 shares at $0.31 per share price.
Shares of Cytori Therapeutics Inc (CYTX) ended Friday, May 13, 2016 session in red amid volatile trading. The shares closed down -0.05 points or -1.85% at $2.66 with 3,89,930 shares getting traded. Post opening the session at $2.71, the shares hit an intraday low of $2.3899 and an intraday high of $2.7499 and the price vacillated in this range throughout the day. The company has a market cap of $35 M and the number of outstanding shares has been calculated to be 1,33,33,369 shares. The 52-week high of Cytori Therapeutics Inc is $11.249943 and the 52-week low is $1.91999.
Cytori Therapeutics Inc. (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product Cytori Cell Therapy for patients with scleroderma hand dysfunction orthopedic disorders cardiovascular disease urinary incontinence and thermal burns combined with radiation injury. The Company commercializes the Celution System under select medical device approvals clearances and registrations to research customers developing new therapeutic applications for Cytori Cell Therapy in Europe Japan and other regions. The Company offers ECCO-50 a cure for knee osteoarthritis which is in ECCO-50 Phase IIA/B of development. It offers ECCI-50 a cure for urinary incontinence which is in Phase II/III of development. The Company is also developing DCCT-10 a cure for cutaneous thermal injury.